MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

The novel Parkinson´s disease locus RIT2 and alpha-synuclein function in intersecting pathways

M. Volta, J. Obergasteiger, C. Überbacher, C. Ascione, C. Corti, A. Hicks, P. Pramstaller (Bolzano, Italy)

Meeting: 2017 International Congress

Abstract Number: 512

Keywords: Alpha-synuclein, Neurophysiology, Synucleinopathies

Session Information

Date: Tuesday, June 6, 2017

Session Title: Parkinson's Disease: Pathophysiology

Session Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Objective: We aim to describe the molecular pathways at the crossroad of etiology and susceptibility in PD, focusing on Rin, coded by the recently associated locus RIT2, and its interaction with alpha-synuclein (aSyn).

Background: A disease-modifying therapy based on a pathogenic mechanism currently represents the main clinical need in PD. Accumulation of aSyn is the hallmark pathology of PD but its biology is still unclear. The protein Rin is a small GTPase that couples nerve growth factor (NGF) stimulation to ERK and p38 MAPK pathways. Its role in the PD context is currently unknown.

Methods: Ric (the Rin ortholog) was silenced in D. melanogaster expressing human aSyn and subjected to negative geotaxis. Cell lines stably expressing wild-type and A53T aSyn (SK-N-SH) or Rin (SH-SY5Y) were obtained. SH-SY5Y cells expressing wild-type and G2019S LRRK2 were kindly provided by Dr. Evy Lobbestael (University of Leuven). Protein and mRNA levels were analyzed by western blotting and real-time PCR, respectively, while immunocytochemistry was performed to assess single cell protein expression. Kinase activation was measured using the AlphaScreen SURE fire assay (Perkin Elmer).

Results: Silencing of Ric in flies ameliorated aSyn-induced climbing deficit. RIT2 mRNA levels are reduced in aSyn and LRRK2 cell lines, but NGF is able to stimulate kinase activation. Further, basal p38 activity is enhanced in Rin cells. Lastly, LRRK2-G2019S (but not wild-type) cells display pSer129-aSyn positive intracellular staining. In a preliminary experiment, transient overexpression of Rin-GFP (but not GFP alone) seems to reduce the percentage of GFP+ cells with pSer129-aSyn staining.

Conclusions: We show that Rin functionally affects aSyn biology. In addition, we confirm NGF activates Rin-ERK/p38 MAPK pathways. Future experiments will investigate the role of this pathway on synaptic transmission. Importantly, Rin appears to have a role in the phosphorylation/aggregation of aSyn in cell lines, triggered by another etiological cause of PD, (G2019S-LRRK2). Collectively, a common pathological pathway involving these proteins seems to occur in cells.

To cite this abstract in AMA style:

M. Volta, J. Obergasteiger, C. Überbacher, C. Ascione, C. Corti, A. Hicks, P. Pramstaller. The novel Parkinson´s disease locus RIT2 and alpha-synuclein function in intersecting pathways [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/the-novel-parkinsons-disease-locus-rit2-and-alpha-synuclein-function-in-intersecting-pathways/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-novel-parkinsons-disease-locus-rit2-and-alpha-synuclein-function-in-intersecting-pathways/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley